Spark's Gene Therapy Hemophilia Data Give Investors The Jitters
Company explains how it will design upcoming Phase III hemophilia A study of SPK-8011 for success, but some analysts still think it's risky business.
Company explains how it will design upcoming Phase III hemophilia A study of SPK-8011 for success, but some analysts still think it's risky business.